Michael A. Mussallem Sells 32,800 Shares of Edwards Lifesciences Corp (EW) Stock

Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $114.97, for a total value of $3,771,016.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Michael A. Mussallem also recently made the following trade(s):

  • On Tuesday, December 19th, Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.82, for a total value of $3,766,096.00.
  • On Monday, November 20th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The shares were sold at an average price of $106.86, for a total value of $3,515,694.00.
  • On Monday, October 30th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The shares were sold at an average price of $100.93, for a total value of $3,320,597.00.

Shares of Edwards Lifesciences Corp (NYSE:EW) opened at $118.14 on Tuesday. Edwards Lifesciences Corp has a twelve month low of $86.55 and a twelve month high of $121.45. The company has a market capitalization of $25,000.00, a P/E ratio of 34.34, a P/E/G ratio of 1.86 and a beta of 0.51. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. During the same period in the previous year, the firm earned $0.68 EPS. Edwards Lifesciences’s revenue for the quarter was up 11.1% on a year-over-year basis. analysts expect that Edwards Lifesciences Corp will post 3.76 EPS for the current year.

Edwards Lifesciences announced that its Board of Directors has approved a stock buyback program on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its shares are undervalued.

Several equities analysts have recently issued reports on EW shares. Canaccord Genuity reiterated a “buy” rating and set a $155.00 price objective on shares of Edwards Lifesciences in a research report on Sunday, October 8th. Cowen reiterated a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, October 12th. Barclays reduced their price objective on Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 25th. JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, Deutsche Bank reduced their price objective on Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research report on Thursday, October 26th. Six investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $129.57.

A number of large investors have recently made changes to their positions in EW. ETF Managers Group LLC bought a new position in shares of Edwards Lifesciences in the second quarter valued at $112,000. MPS Loria Financial Planners LLC bought a new position in shares of Edwards Lifesciences in the second quarter valued at $140,000. Dupont Capital Management Corp bought a new position in shares of Edwards Lifesciences in the third quarter valued at $142,000. Captrust Financial Advisors bought a new position in shares of Edwards Lifesciences in the second quarter valued at $149,000. Finally, Salem Investment Counselors Inc. increased its holdings in shares of Edwards Lifesciences by 16.3% in the second quarter. Salem Investment Counselors Inc. now owns 1,419 shares of the medical research company’s stock valued at $168,000 after buying an additional 199 shares in the last quarter. 81.36% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.com-unik.info/2018/01/09/michael-a-mussallem-sells-32800-shares-of-edwards-lifesciences-corp-ew-stock.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit